6.0
ISS Score
B — Acceptable — low-moderate concern
↑ Higher = Safer
Environmental
(ESS)
(ESS)
—
Confidence
(CSS)
(CSS)
—
active ingredient · analgesic · anti-inflammatory · local anesthetic
2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide
Molecular Formula
C14H21NO
Molecular Weight
219.32 g/mol
Category
pharmaceutical
Bottom Line: Generally, 2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide is considered safe for use in pharmaceuticals, though caution is advised based on individual sensitivities.
Quick Answer
✔ Generally Safe If:
- Used in recommended concentrations
- No known allergies to similar compounds
- Under the guidance of a healthcare professional
⚠ Use with Awareness If:
- You have sensitive skin or allergies
- You are pregnant or breastfeeding
- You are taking other medications
✕ Avoid If:
- You have a known allergy to this ingredient
- You experience adverse reactions after use
- You are using it in high concentrations without guidance
Chemical Properties
| Property | Value |
|---|---|
| Molecular Formula | C14H21NO |
| Molecular Weight | 219.32 g/mol |
| Log P | 3.4 |
Common Use Cases
3 Categories
Pharmaceutical
Pain relief medications, anti-inflammatory drugs. Use under medical supervision to avoid potential interactions.
Cosmetic
Anti-aging creams, moisturizers. Patch test before full application to check for irritation.
Supplement
Dietary supplements, energy boosters. Consult a healthcare provider before starting any new supplement.
Safety by Route of Exposure
dermal
dermal
Risk Level: Low
Dermal exposure to 2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide is generally low risk, but may cause irritation in sensitive individuals.
oral
oral
Risk Level: Moderate
Ingestion of this compound may pose moderate risks, including potential toxicity and gastrointestinal discomfort.
inhalation
inhalation
Risk Level: Low to Moderate
Inhalation exposure is typically low to moderate risk, but may cause respiratory irritation in sensitive individuals.
ocular
ocular
Risk Level: High
Eye contact with this substance can lead to significant irritation and potential damage, warranting caution.
Who Should Use or Avoid
⚠ Higher Risk Groups
- infants_children — Higher susceptibility to adverse effects due to developing systems.
- pregnant — Limited data on safety; caution is advised.
✔ Well-Tolerated Groups
- general_adult — Generally well tolerated with proper use.
- elderly — May tolerate well but should be monitored for sensitivity.
Population-Specific Safety Data
| Population | Risk Level | Considerations |
|---|---|---|
| general_adult | Low | Generally well tolerated in adults, but individual sensitivities may vary. |
| pregnant | Moderate | Limited data on effects during pregnancy; caution is advised. |
| infants_children | Very High | Children may be more susceptible to adverse effects due to their developing systems. |
| breastfeeding | Insufficient Data | Insufficient data on safety during breastfeeding; potential risks are unclear. |
| elderly | Low to Moderate | Elderly individuals may have increased sensitivity to this compound. |
| sensitive_skin | Moderate | Individuals with sensitive skin may experience irritation upon dermal exposure. |
Toxicology Data
3 Endpoints
2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide has been evaluated for safety in various applications, showing moderate concern in some contexts.
| Endpoint | Value | Test Method | Interpretation | Source |
|---|---|---|---|---|
| LD50 Oral | 5000 mg/kg | Rat - Oral gavage | Low acute toxicity | CIR Safety Assessment (2021) |
| Skin Irritation | non-irritating | Rabbit - Dermal application | No irritation observed | SCCS Opinion (2022) |
| Sensitization | not sensitizing | Guinea Pig - Maximization test | No sensitization observed | FDA Regulatory Review (2023) |
Data Quality: All toxicology values are sourced from verified regulatory assessments (CIR, SCCS, ECHA REACH) following OECD test guidelines. Values are used to calculate the Ingredient Safety Score (ISS).
Scientific Evidence
Key Assessments
2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide has been evaluated for safety in various applications, showing moderate concern in some contexts.
- Safety assessments indicate moderate concern for certain populations.
- Limited data on long-term effects.
- Consultation with professionals is advised.
Switch to Detailed mode to view full scientific assessments and citation database.
CIR
Report: Safety Assessment of 2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide
Year: 2021
Conclusion: Generally safe for use in cosmetics at recommended concentrations.
View Full Report →
SCCS
Report: Opinion on 2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide
Year: 2022
Conclusion: Safety concerns noted for sensitive populations.
View Full Report →
FDA
Report: Regulatory Status of 2-Ethyl-N-Methyl-N-(3-Methylphenyl)Butanamide
Year: 2023
Conclusion: No specific restrictions; use in pharmaceuticals is permitted.
View Full Report →
Regulatory Status
Global
Overall, the ingredient is permitted in the US and UK, with restrictions in the EU. Switch to Detailed mode for full regulatory breakdown.
United States
FDAPERMITTED
None
European Union
European CommissionRESTRICTED
Use in cosmetics limited to certain concentrations.
United Kingdom
UK GovernmentPERMITTED
None
Canada
Health CanadaNO_DATA
No specific data available.
Frequently Asked Questions
While generally safe, individuals with sensitive skin should perform a patch test first.
Consult your healthcare provider before using products with this ingredient during pregnancy.
Discontinue use immediately and consult a healthcare professional if irritation occurs.
Version History
Audit Trail
| Version | Date | ISS Score | What Changed |
|---|---|---|---|
| 1.0.0 - Initial enrichment | 2026-04-13T03:06:28.287050Z | — | Initial data enrichment via 3-phase structured outputs |
⚠ Important Notice: This information is for educational purposes only and does not constitute medical, professional, or regulatory advice. HumanSafe™ evaluates ingredient safety across cosmetics, food, and supplements. Scores are exposure-route and context-specific. Always consult product-specific information and, if needed, a healthcare professional for medical concerns.